Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP19986 in Patients With Gastroesophageal Reflux Disease
NCT00838396Phase 2Completed
- Sponsor
- Indivior
- Start
- Oct 2005
- Primary completion
- Aug 2006
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen placarbil in gastroesophageal reflux disease (GERD), sponsored by Indivior. Started Oct 2005; status: completed.
02
Drugs
arbaclofen placarbil
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00838396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838396.